Details of remuneration Amounts of remuneration Details of the remuneration of key management personnel of the consolidated entity are set out in the following tables. The key management personnel of the consolidated entity consisted of the following directors and executives of Noxopharm Limited: • Mr. Frederic Bart - Non Executive Chairman • Mr. Peter Marks - Non Executive Director and Deputy Chairman • Mr. Boris Patkin - Non Executive Director • Dr. Gisela Mautner - Chief Executive Officer and Managing Director Short-term benefits Postemployment benefits Long-term benefits Share-based payments Cash salary and fees Cash bonus Non- monetary* Super-annuation Long service leave Equity- settled Total $ $ $ $ $ $ $ 2025 Directors: Mr. Frederic Bart 40,359 - - 4,641 - - 45,000 Mr. Peter Marks 60,000 - - - - - 60,000 Mr. Boris Patkin 45,000 - - - - - 45,000 Dr. Gisela Mautner 439,710 - 121 50,567 8,223 37,905 536,526 585,069 - 121 55,208 8,223 37,905 686,526 * provision for annual leave Short-term benefits Postemployment benefits Long-term benefits Share-based payments Cash salary and fees Cash bonus Non- monetary* Super-annuation Long service leave Equity- settled Total $ $ $ $ $ $ $ 2024 Directors: Mr. Frederick Bart 40,541 - - 4,459 - - 45,000 Mr. Peter Marks 60,000 - - - - - 60,000 Mr. Boris Patkin 45,000 - - - - - 45,000 Dr. Gisela Mautner 472,250 - (31,538) 51,947 7,964 - 500,623 617,791 - (31,538) 56,406 7,964 - 650,623 *provision for annual leave - credit due to annual leave cashed out. The proportion of remuneration linked to performance and the fixed proportion are as follows: Fixed remuneration At risk - STI At risk - LTI 2025 2024 2024 2024 2025 2024 Directors: Mr. Frederic Bart 100% 100% - - - - Mr. Peter Marks 100% 100% - - - - Mr. Boris Patkin 100% 100% - - - - Dr. Gisela Mautner 93% 100% 7% - - - Annual Report 2025 18
RkJQdWJsaXNoZXIy MjE2NDg3